Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. AegirBio AB (publ)
  6. News
  7. Summary
    AEGIR   SE0014401121

AEGIRBIO AB (PUBL)

(AEGIR)
Delayed Nasdaq Stockholm  -  11:24 2022-12-08 am EST
4.900 SEK   +0.80%
11/23AegirBio AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
10/24AegirBio Shares Gain 13% on Approval to Prolong Shelf Life of COVID-19 Antigen Tests
MT
10/24AegirBio has received approval from the Notified Body to prolong the shelf life of its Covid-19 antigen test
AQ
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

AegirBio and iSTOC to cooperate with a data management platform

09/06/2022 | 04:30am EST

PRESSRELEASE       September 6, 2022

AegirBio AB is pleased to announce the initiation of a development and licensing agreement with iSTOC. The agreement covers the development of a data management platform for the recently CE-marked Magnia® Reader based natalizumab Point of Care (POC) therapeutic drug monitoring (TDM) test.

The deliverables will include a web-based information dashboard and a mobile app to upload data readouts from the Magnia Reader. This platform will provide an interface between electronic medical records and be a foundation for easy integration of our assays into clinical, POC, and at-home workflows, both for upcoming trials and everyday patient care.

"In modern Point of Care and Point of Need testing, data management and presentation are as important as the accuracy of the test. We reviewed many potential solutions and ultimately chose the iSTOC platform because of its flexibility, data security, and established regulatory compliance." said Bradley Messmer, CEO of AegirBio.

He added "With real world clinical studies about to begin, we identified that it was critical to get this component of our total solution in development. A successful project with this product will open the door for future collaborations with our growing portfolio of assays and we look forward to a fruitful partnership with the iSTOC team".

Jarmo Järvenpää, the CEO of iSTOC stated "We are looking forward to developing the platform with AegirBio. We are excited to start collaborating with AegirBio and combining our strengths in this information dashboard and mobile app project, as well as in future ventures under discussion." 

For further information, please contact: ir@AegirBio.com

About iSTOC

iSTOC is a global player in mobile Point of Care (POC) diagnostics by transforming disconnected data into relevant and actionable information.  By integrating mobile technologies with smart services iSTOC has deployed and is deploying POC services to both consumers and professional users. IDA (Immediate Diagnostics and Analytics) Platform integrates Point of Care diagnostics, AI, mobile technology and cloud computing into one reliable platform, which ensures that accurate data is immediately available and actionable. www.istoc.io.

About AegirBio

AegirBio is a Swedish diagnostics company that was founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results.

https://news.cision.com/aegirbio/r/aegirbio-and-istoc-to-cooperate-with-a-data-management-platform,c3626516

https://mb.cision.com/Main/19599/3626516/1623585.pdf

(c) 2022 Cision. All rights reserved., source Press Releases - English

All news about AEGIRBIO AB (PUBL)
11/23AegirBio AB Reports Earnings Results for the Third Quarter and Nine Months Ended Septem..
CI
10/24AegirBio Shares Gain 13% on Approval to Prolong Shelf Life of COVID-19 Antigen Tests
MT
10/24AegirBio has received approval from the Notified Body to prolong the shelf life of its ..
AQ
10/24AegirBio Receives Approval from the Notified Body to Prolong the Shelf Life of Its Covi..
CI
10/14AegirBio announces first clinical saliva TDM study in US
AQ
10/14AegirBio Announces First Clinical Saliva TDM Study in US
CI
09/06AegirBio presentation and discussion session at ECTRIMS 2022
AQ
09/06AegirBio and iSTOC to cooperate with a data management platform
AQ
09/06AegirBio and iSTOC to Cooperate with Data Management Platform
CI
08/25AegirBio AB Reports Earnings Results for the Second Quarter and Six Months Ended June 3..
CI
More news
Financials
Sales 2021 13,3  1,28  1,28 
Net income 2021 -92,3 M -8,92 M -8,92 M
Net cash 2021 32,6 M 3,15 M 3,15 M
P/E ratio 2021 -9,29x
Yield 2021 -
Capitalization 104 M 10,1 M 10,1 M
EV / Sales 2020 -
EV / Sales 2021 72 019 947x
Nbr of Employees 17
Free-Float 78,5%
Chart AEGIRBIO AB (PUBL)
Duration : Period :
AegirBio AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AEGIRBIO AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Bradley Messmer Director, Chief Executive & Scientific Officer
Patrik Gotthardt Chief Financial Officer
Karl Anders Ísten Ingvarsson Chairman
Jens Patrik Elfwing Chief Operating Officer
Seppo Olavi Mńkinen Independent Director
Sector and Competitors
1st jan.Capi. (M$)
AEGIRBIO AB (PUBL)-91.49%10
THERMO FISHER SCIENTIFIC-16.35%219 934
DANAHER CORPORATION-18.47%195 269
INTUITIVE SURGICAL, INC.-25.42%94 693
BOSTON SCIENTIFIC CORPORATION6.31%65 356
SIEMENS HEALTHINEERS AG-25.07%57 925